Growing pipeline of TYK2 inhibitors behind BMS’s Sotyktu 

FDA’s approval of BMS’ TYK2 inhibitor Sotyktu has de-risked the inflammation and autoimmunity target. Coming up behind Sotyktu is a class of at least 11 additional TYK2 inhibitors that have started clinical trials, including three that are dual inhibitors of JAK1 and TYK2.  

FDA approved Sotyktu deucravacitinib from Bristol Myers Squibb Co. (NYSE:BMY) late Friday for moderate-to-severe plaque psoriasis, making it the first TYK2 inhibitor to be approved in the U.S., and the second oral therapy approved for psoriasis after Otezla apremilast. Sotyktu showed superior response rates to Otezla in the Phase III POETYK PSO-1 and POETYK PSO-2 studies...